Jasper Therapeutics (NASDAQ:JSPR) Stock Rating Lowered by Wall Street Zen

Jasper Therapeutics (NASDAQ:JSPR) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other research analysts also recently weighed in on the company. TD Cowen downgraded Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Royal Bank Of Canada set a $3.00 price objective on Jasper Therapeutics and gave the company a “sector perform” rating in a research note on Friday, May 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Finally, Piper Sandler assumed coverage on Jasper Therapeutics in a research report on Wednesday. They set an “overweight” rating and a $2.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Jasper Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $8.17.

Jasper Therapeutics Stock Performance

NASDAQ:JSPR opened at $0.79 on Friday. The stock has a market capitalization of $22.12 million, a price-to-earnings ratio of -0.50 and a beta of 3.02. The firm has a fifty day simple moving average of $0.59 and a two-hundred day simple moving average of $0.90. Jasper Therapeutics has a 12 month low of $0.32 and a 12 month high of $3.14.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. Equities analysts predict that Jasper Therapeutics will post -1.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Jasper Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Knott David M Jr lifted its stake in Jasper Therapeutics by 5.8% during the 4th quarter. Knott David M Jr now owns 181,389 shares of the company’s stock valued at $332,000 after acquiring an additional 10,000 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Jasper Therapeutics in the 1st quarter worth $46,000. Engineers Gate Manager LP bought a new stake in shares of Jasper Therapeutics in the 2nd quarter worth $78,000. Renaissance Technologies LLC raised its holdings in shares of Jasper Therapeutics by 9.0% in the fourth quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock valued at $416,000 after purchasing an additional 18,683 shares during the last quarter. Finally, Panagora Asset Management Inc. purchased a new stake in shares of Jasper Therapeutics in the fourth quarter valued at about $35,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.